Citations

Showing 10 of 108094 citations.

GMPR: A robust normalization method for zero-inflated count data with application to microbiome sequencing data
Reeve, James , Zhang, L. , Huang, Shengbing, Wang, Xuefeng , Chen, Li , Chen, Jun

Mayo Clinic

No container title available | March 7, 2018 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7287/peerj.preprints.3417v3 Get It

Normalization is the first critical step in microbiome sequencing data analysis used to account for variable library sizes. Current RNA-Seq based normalization methods that have been adapted for microbiome data fail to consider the unique characteristics of microbiome data, which contain a vast number of zeros due to the physical absence or under-sampling of the microbes. Normalization methods that specifically address the zero inflation remain largely undeveloped. Here we propose GMPR - a simple but effective normalization method - for zero-inflated sequencing data such as microbiome data. Simulation studies and real datasets analyses demonstrate that the proposed method is more robust than competing methods, leading to more powerful detection of differentially abundant taxa and higher reproducibility of the relative abundances of taxa.
Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis
Mouchli, Mohamad, Singh, Siddharth , Boardman, Lisa, Bruining, David H. , Rosen, Charles B. , Poterucha, John J., Watt, Kymberly D. , Kane, Sunanda V. , Raffals, Laura E. , Loftus, Edward V. , Mouchli, Mohamad A, Hasan, Bashar , Loftus, Edward V , Boardman, Lisa, Lightner, Amy L. , Heimbach, Julie K. , Hasan, Bashar

Mayo Clinic

Inflammatory Bowel Diseases | March 7, 2018 | Volume: 24 | Issue: 5 | Pages: 1074-1081

10.1093/ibd/izx096 | PMID 29522202 Get It

Hospital Utilization in Patients With Gastric Cancer and Factors Affecting In-Hospital Mortality, Length of Stay, and Costs
Sarvepalli, Shashank , Garg, Sushil Kumar , Sarvepalli, Siri S. , Anugwom, Chimaobi M. , Thota, Prashanthi N. , Sanaka, Madhusudhan R. , Garg, Sushil K, Wadhwa, Vaibhav

Mayo Clinic

Journal of Clinical Gastroenterology | March 6, 2018 | Volume: 53 | Issue: 4 | Pages: e157-e163

10.1097/mcg.0000000000001016 | PMID 29517707 Get It

Introduction: Although gastric cancer (GC) rates have been declining in the United States, it continues to be a major cause of morbidity. This study examined trends in hospital admissions, in-hospital mortality, length of stay (LOS), and inpatient costs related to GC. In addition, various factors associated with in-hospital mortality, LOS, and inpatient costs were examined. Methods: National inpatient sample—the largest publicly available all-payer inpatient care database—was interrogated to obtain information about various demographic and hospital-related factors (including those mentioned above) in patients who were primarily admitted for GC between the years 1998 to 2013. These trends were analyzed. Multivariate analysis was also performed to identify risk factors associated with LOS, costs, and mortality. Results: A total of 679,330 hospital discharges with the principal diagnosis of GC were obtained. Hospital stays increased by approximately 340 stays per year (±110; P=0.00079). However, inpatient mortality rate and LOS declined by 0.36% per year (±0.024%; P<0.0001), and 0.11 days per year (±0.01; P<0.0001), respectively. The inpatient charges have increased at the rate of $3241 per year (±133.3; P<0.0001). Differences in mortality rate, LOS, and inpatient costs were affected by multiple factors. Conclusions: Despite the overall decline in GC incidence, the incidence of hospitalizations per 100,000 US population related to GC did not change significantly. Although LOS and mortality declined, inpatient charges increased over the study period.
Esophageal Food Impaction
Melendez-Rosado, José , Patel, Sheetal , Badillo, Raul, Francis, Dawn L., Corral, Juan E. , Francis, Dawn

Mayo Clinic

Journal of Clinical Gastroenterology | March 6, 2018 | Volume: 53 | Issue: 3 | Pages: 179-183

10.1097/mcg.0000000000001004 | PMID 29517706 Get It

Goals: The goal of this study is to examine the causes, type of adverse events (AE), and effects of elective intubation in outcomes associated with esophageal food impaction (EFI). Background: EFI is a gastrointestinal emergency requiring immediate medical attention. Study: Retrospective review of all EFI cases presenting at 3 large tertiary centers from October 1, 2011 to October 31, 2014 and all cases registered in the Clinical Outcome Research Initiative (CORI) database from January 1, 2000 to December 31, 2012. Statistical analysis compared health care utilization, AEs, and outcomes in patients with or without elective intubation. Results: A total of 214 cases presenting with EFI at our 3 referral hospitals and 4950 cases in the CORI database met inclusion criteria. Prevalence of structural disorders was similar in the Mayo Clinic and CORI datasets: 24.3% and 27.7% had strictures, and 3.8% and 2.5% had a tumor, respectively. AEs in the nonintubation group were 14.7% compared with 33.3% in the elective intubation group (P=0.003); however, 71.0% of these events were associated with EFI itself and not therapeutic procedure. Esophageal AEs were common (15.0%), followed by pulmonary and cardiovascular events with 3.0% and 1.4%, respectively. Severity of the AEs was influenced by the impaction-to-endoscopy time. Conclusions: Prevalence of structural esophageal disorders was similar to previous smaller studies. Elective intubation was associated with increased AEs; however, this is felt to be because of the nature of EFI itself and not by therapeutic endoscopy. Prolonged impaction-to-endoscopy time was associated with severe AEs.
Constitutive Interferon Pathway Activation in Tumors as an Efficacy Determinant Following Oncolytic Virotherapy
Kurokawa, Cheyne, Iankov, Ianko, Anderson, S. Keith , Aderca, Ileana, Leontovich, Alexey A. , Oberg, Ann L. , Greiner, Suzanne , Becker, Marc A., Thompson, E. Aubrey , Haluska, Paul , Jentoft, Mark E. , Weroha, S. John , Jen, Jin , Iankov, Ianko D, Schroeder, Mark A. , Greiner, Suzanne M, Galanis, Evanthia , Maurer, Matthew J. , Giannini, Caterina , Parney, Ian F. , Sarkaria, Jann N.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 6, 2018 | Volume: 110 | Issue: 10 | Pages: 1123-1132

10.1093/jnci/djy033 | PMID 29788332 Get It

Transitioning to Medical School: Growth During the Application Cycle
Kiessling, Patrick

Mayo Clinic

Academic Medicine | March 6, 2018 | Volume: 93 | Issue: 6 | Pages: 820-820

10.1097/acm.0000000000002186 | PMID 29517527 Get It

Partial loss of function of colony‐stimulating factor 1 receptor in a patient with white matter abnormalities
Miura, Takeshi , Harriott, Andrea M. , Mezaki, Naomi , Rademakers, Rosa , Ross, Owen A. , Ikeuchi, Takeshi , Wszołek, Zbigniew K. , Ikeuchi, T , Wszolek, Z.K. , Ross, Owen A , Konno, Takuya , Edwards, E. S., Meschia, James F.

Mayo Clinic

European Journal of Neurology | March 6, 2018 | Volume: 25 | Issue: 6 | Pages: 875-881

10.1111/ene.13611 | PMID 29509319 Get It

Background and purposeMutations in colony‐stimulating factor 1 receptor (CSF1R) cause adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Patients with ALSP can be misdiagnosed as having acute ischemic stroke due to hyperintensity lesions on diffusion‐weighted magnetic resonance imaging. Mutant CSF1R proteins identified in ALSP show a complete loss of autophosphorylation of CSF1R.MethodsWe conducted mutation screening of CSF1R in 123 patients with definite acute ischemic cerebrovascular syndrome and positive family history of stroke. The pathogenicity of identified variants was evaluated using functional analyses. The levels of autophosphorylation of CSF1R in response to treatment with ligands of CSF1R were examined in cells transfected with wild‐type and mutant CSF1R.ResultsWe identified eight CSF1R variants, six were known non‐pathogenic polymorphisms, whereas the other two were missense variants inducing substitution of amino acid residues (p.Glu573Lys and p.Gly747Arg). Functional assay showed that the levels of autophosphorylation of p.Gly747Arg were similar to those of wild‐type when treated with ligands. The autophosphorylation of p.Glu573Lys was detectable, but significantly decreased compared with those of wild‐type CSF1R (P < 0.001, two‐way anova with Bonferroni). The clinical presentation of the patient with p.Glu573Lys was consistent with cerebral embolism. The patient did not have typical clinical findings of ALSP. However, periventricular white matter abnormalities, unrelated to the recent infarct, were evident on brain magnetic resonance imaging.ConclusionsIn contrast to ALSP‐associated missense mutations, CSF1R p.Glu573Lys variant in a patient with acute ischemic cerebrovascular syndrome showed a partial loss of autophosphorylation of CSF1R; its clinical significance warrants further investigation.
Trial Readiness in Cavernous Angiomas With Symptomatic Hemorrhage (CASH)
Polster, Sean P. , Flemming, Kelly D. , Girard, Romuald , Hanley, Daniel F. , Hobson, Nicholas , Kim, Helen , Koskimäki, Janne , Lane, Karen , McBee, Nichol , Stadnik, Agnieszka , Thompson, Richard E. , Zabramski, Joseph M. , Zeineddine, Hussein A. , Awad, Issam A. , Flemming, Kelly, Girard, Romuald , Hanley, Daniel F , Cao, Ying , Carroll, Timothy , Koenig, James I. , Majersik, Jennifer Juhl , Morrison, Leslie , Shenkar, Robert , Flemming, Kelly D , Kim, Helen , Polster, Sean P

Mayo Clinic

Neurosurgery | March 6, 2018 | Volume: 84 | Issue: 4 | Pages: 954-964

10.1093/neuros/nyy108 | PMID 29660039 Get It

Abstract BACKGROUND Brain cavernous angiomas with symptomatic hemorrhage (CASH) are uncommon but exact a heavy burden of neurological disability from recurrent bleeding, for which there is no proven therapy. Candidate drugs to stabilize the CASH lesion and prevent rebleeding will ultimately require testing of safety and efficacy in multisite clinical trials. Much progress has been made in understanding the epidemiology of CASH, and novel biomarkers have been linked to the biological mechanisms and clinical activity in lesions. Yet, the ability to enroll and risk-stratify CASH subjects has never been assessed prospectively at multiple sites. Biomarkers and other outcomes have not been evaluated for their sensitivity and reliability, nor have they been harmonized across sites. OBJECTIVE To address knowledge gaps and establish a research network as infrastructure for future clinical trials, through the Trial Readiness grant mechanism, funded by National Institute of Neurological Disorders and Stroke/National Institutes of Health. METHODS This project includes an observational cohort study to assess (1) the feasibility of screening, enrollment rates, baseline disease categorization, and follow-up of CASH using common data elements at multiple sites, (2) the reliability of imaging biomarkers including quantitative susceptibility mapping and permeability measures that have been shown to correlate with lesion activity, and (3) the rates of recurrent hemorrhage and change in functional status and biomarker measurements during prospective follow-up. EXPECTED OUTCOMES We propose a harmonized multisite assessment of enrollment rates of CASH, baseline features relevant to stratification in clinical trials, and follow-up assessments of functional outcomes in relation to clinical bleeds. We introduce novel biomarkers of vascular leak and hemorrhage, with firm mechanistic foundations, which have been linked to clinical disease activity. We shall test their reliability and validity at multiple sites, and assess their changes over time, with and without clinical rebleeds, hence their fitness as outcome instruments in clinical trials. DISCUSSION The timing cannot be more opportune, with therapeutic targets identified, exceptional collaboration among researchers and the patient community, along with several drugs ready to benefit from development of a path to clinical testing using this network in the next 5 years.
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
Shapiro, Geoffrey I. , Bullock, Andrea J. , Rock, Edwin P. , Elekes, Agnes, Lin, Chester, Kostic, Dušan , Ohi, Naoto, Rasco, Drew , Papadopoulos, Kyriakos P. , Patnaik, Amita , Smith, Lon, Tolcher, Anthony W. , Flaherty, Keith T. , Berlin, Jordan D. , Witzig, Thomas E. , Habermann, Thomas M. , Ohi, Naoto, Coté, Gregory M. , Shapiro, Geoffrey I

Mayo Clinic

The Oncologist | March 6, 2018 | Volume: 23 | Issue: 6 | Pages: 658-e72

10.1634/theoncologist.2017-0325 | PMID 29511132 Get It

Abstract Lessons Learned OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation that exhibited promising anticancer activity in preclinical models. In this first-in-human phase I study of OPB-111077 in unselected advanced cancers, treatment-emergent adverse events, most frequently nausea, fatigue, and vomiting, were generally mild to moderate in intensity and could be medically managed. Overall, only modest clinical activity was observed after OPB-111077 given as monotherapy. Notable antitumor activity was seen in a subject with diffuse large B-cell lymphoma. Background OPB-111077 is a novel inhibitor of STAT3 and mitochondrial oxidative phosphorylation with promising anticancer activity in preclinical models. Methods Open-label, phase I trial of OPB-111077 in advanced cancers with no available therapy of documented benefit. Initial dose escalation in unselected subjects was followed by dose expansion. Patients received oral OPB-111077 daily in 28-day cycles until loss of clinical benefit. Results Eighteen subjects enrolled in dose escalation, and 127 in dose expansion. Dose-limiting toxicities were observed at 300 mg and 400 mg QD; maximum tolerated dose was defined as 250 mg QD. Frequently reported treatment-emergent adverse events (TEAEs) included nausea, fatigue, and vomiting. TEAEs were generally mild to moderate and could be medically managed. OPB-111077 reached micromolar drug concentrations, had an elimination half-life of approximately 1 day, and reached steady-state by day 8. A durable partial response was observed in one subject with diffuse large B-cell lymphoma. Seven subjects with diverse tumor types had stable disease or minor responses for at least eight treatment cycles (224 days). Conclusion OPB-111077 is generally well tolerated, and its pharmacokinetic profile is sufficient for further clinical development. Notable clinical activity was observed in a subject with diffuse large B-cell lymphoma. Overall, modest efficacy was observed against unselected tumors.